{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:19:10Z","timestamp":1783358350165,"version":"3.54.6"},"reference-count":32,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Employing a simple synthetic protocol, a series of highly effective halogen-substituted imidazole-thiosemicarbazides with anti-Toxoplasma gondii effects against the RH tachyzoites, much better than sulfadiazine, were obtained (IC50s 10.30\u2014113.45 \u00b5g\/mL vs. ~2721.45 \u00b5g\/mL). The most potent of them, 12, 13, and 15, blocked the in vitro proliferation of T. gondii more potently than trimethoprim (IC50 12.13 \u00b5g\/mL), as well. The results of lipophilicity studies collectively suggest that logP would be a rate-limiting factor for the anti-Toxoplasma activity of this class of compounds.<\/jats:p>","DOI":"10.3390\/molecules24081618","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T03:02:59Z","timestamp":1556161379000},"page":"1618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Discovery of Potent and Selective Halogen-Substituted Imidazole-Thiosemicarbazides for Inhibition of Toxoplasma gondii Growth In Vitro via Structure-Based Design"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-7702","authenticated-orcid":false,"given":"Agata","family":"Paneth","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3114-0623","authenticated-orcid":false,"given":"Lidia","family":"W\u0119gli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-1074","authenticated-orcid":false,"given":"Adrian","family":"Bekier","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Stefaniszyn","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1934","authenticated-orcid":false,"given":"Monika","family":"Wujec","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazar","family":"Trotsko","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hawry\u0142","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Hawry\u0142","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Dzitko","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: From animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1574-6976.2011.00305.x","article-title":"Mechanisms of Toxoplasma gondii persistence and latency","volume":"36","author":"Sullivan","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/clinids\/15.2.211","article-title":"Toxoplasmic encephalitis in AIDS","volume":"15","author":"Luft","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","first-page":"322","article-title":"Toxoplasmosis in the non-AIDS immunocompromised host","volume":"13","author":"Israelski","year":"1993","journal-title":"Curr. Clin. Top Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2011.10.018","article-title":"Congenital parasitic infections: A review","volume":"121","author":"Carlier","year":"2012","journal-title":"Acta Trop."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ijpara.2008.03.007","article-title":"Toxoplasma gondii infection in humans and animals in the United States","volume":"38","author":"Dubey","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.actatropica.2018.04.026","article-title":"Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis","volume":"185","author":"Zhang","year":"2018","journal-title":"Acta Trop."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2307\/3284282","article-title":"Oocyst-induced murine Toxoplasmosis: Life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts","volume":"83","author":"Dubey","year":"1997","journal-title":"J. Parasitol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wei, H.X., Wei, S.S., Lindsay, D.S., and Peng, H.J. (2015). A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138204"},{"key":"ref_11","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"CDC MMWR"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1128\/AAC.40.6.1360","article-title":"Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii","volume":"40","author":"Jacobson","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: A systematic review","volume":"17","author":"Goodwin","year":"2017","journal-title":"Drugs R & D"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hiv.12402","article-title":"A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: Is trimethoprim-sulfamethoxazole a real option?","volume":"18","author":"Hernandez","year":"2017","journal-title":"HIV Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Joynson, D.H.M., and Wreghitt, T.G. (2001). Antitoxoplasma chemotherapy. Toxoplasmosis: A Comprehensive Clinical Guide, Cambridge University Press.","DOI":"10.1017\/CBO9780511527005"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/B978-0-444-52910-7.00028-3","article-title":"Congenital toxoplasmosis","volume":"112","author":"Kieffer","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.7b01663","article-title":"Novel molecules to treat chronic central nervous system Toxoplasmosis","volume":"60","author":"Kortagere","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/jm950760y","article-title":"Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations","volume":"39","author":"Piper","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Paneth, A., W\u0119gli\u0144ska, L., Bekier, A., Stefaniszyn, E., Wujec, M., Trotsko, N., and Dzitko, K. (2019). Systematic identification of thiosemicarbazides for inhibition of Toxoplasma gondii. Molecules, 24.","DOI":"10.3390\/molecules24030614"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1002\/anie.200705435","article-title":"A new generation of specific Tryponosoma cruzi trans-sialidase inhibitors","volume":"47","author":"Buchini","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/jm900173b","article-title":"Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models","volume":"52","author":"Bonnefous","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cmdc.200700022","article-title":"Synthesis, cruzain docking, and in vitro studies of aryl-4-oxothiazolylhydrazones against Trypanosoma cruzi","volume":"2","author":"Leite","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cbic.200400017","article-title":"Halogenation of drugs enhances membrane binding and permeation","volume":"5","author":"Gerebtzoff","year":"2004","journal-title":"ChemBioChem"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0196-9781(99)00127-8","article-title":"The effect of halogenation on blood\u2013brain barrier permeability of a novel peptide drug","volume":"20","author":"Gentry","year":"1999","journal-title":"Peptides"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2010.11.010","article-title":"Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety","volume":"46","author":"Plech","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/acs.jpcb.7b02914","article-title":"Predicting a drug\u2019s membrane permeability: A computational model validated with in vitro permeability assay data","volume":"121","author":"Bennion","year":"2017","journal-title":"J. Phys. Chem. B"},{"key":"ref_27","unstructured":"Hansch, C., and Leo, A.J. (1979). Substituent Constant for Correlation Analysis in Chemistry and Biology, Wiley."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kerns, E.H., and Di, L. (2008). Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization, Elsevier.","DOI":"10.1016\/B978-012369520-8.50018-8"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1021\/acs.jmedchem.8b01259","article-title":"Lipophilic permeability efficiency reconciles the opposing roles of lipophilicity in membrane permeability and aqueous solubility","volume":"61","author":"Naylor","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hc.20643","article-title":"Study of direction of cyclization of 1-azolyl-4-aryl\/alkyl-thiosemicarbazides","volume":"21","author":"Siwek","year":"2010","journal-title":"Heteroatom Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.ejmech.2010.05.017","article-title":"Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles","volume":"45","author":"Liesen","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","unstructured":"OECD (2004). Test No. 117: Partition Coefficient (n-octanol\/water), HPLC Method, OECD Guidelines for the Testing of Chemicals, Section 1, OECD Publishing."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/8\/1618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:46:45Z","timestamp":1760186805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/8\/1618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["molecules24081618"],"URL":"https:\/\/doi.org\/10.3390\/molecules24081618","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]}}}